Click me
Transcribed

BOOSTER DOSE OF OPPORTUNITY

BOOSTER DOSE OF OPPORTUNITY 5672.1 Indian companies could reap huge profits with the generic copies of drugs that are set to go off-patent between 2012 and 2016. Here is a snapshot of opportunities for the top six. Figures in crore * Barring Ranbaxy which follows the calendar year as its financial year, revenues for the others are for FY 2010/1 4508.5 5304.41 Graphic by Santosh Kushwaha 27.53 REVENUES 27.18 26.50 Natco 371.74 Pharma Ranbaxy Laboratories 1154.63 3104.7 Glenmark Pharma OVERALL OPPORTUNITY Lupin Pharmaceuticals Ranbaxy Laboratories SHARED OPPORTUNITY* Dr. Reddy's Laboratories 13.54 Sun Pharma Natco Pharma EXCLUSIVE OPPORTUNITY* 3.80 Dr. Reddy's Laboratories 9.6 Glenmark Pharma Natco Pharma 6.58 4.93 0.45 2.10 Sun Pharma No. of brands 3 Lupin Pharmaceuticals 1.70 Lupin Pharmaceuticals 0.26 1.55 No. of brands 2 Ranbaxy Laboratories 28.05 No. of brands 3 No. of brands 12 Glenmark Pharma 4.48 Dr. Reddy's Laboratories Figures in $bn * The company is the sole FTF, or first to file, and has an exclusive right to sell an off-patent drug for 180 days; figures in billion are annual sales in the US. 1.65 27.63 No. of 8 brands No. of brands 3 2 6 No. of brands 4 Sun Pharma 32 17 29 27.79 Figures in $bn Where the company shares the 180-day exclusivity period along with other drug makers, as well as opportunities beyond that period Figures in $bn Source: JM Financial I T I IT Ranbaxy Laboratories Natco Pharma Glenmark Pharma Lupin Pharmaceuticals Or. Reddy's Laboratories Sun Pharma BOOSTER DOSE OF OPPORTUNITY 5672.1 Indian companies could reap huge profits with the generic copies of drugs that are set to go off-patent between 2012 and 2016. Here is a snapshot of opportunities for the top six. Figures in crore * Barring Ranbaxy which follows the calendar year as its financial year, revenues for the others are for FY 2010/1 4508.5 5304.41 Graphic by Santosh Kushwaha 27.53 REVENUES 27.18 26.50 Natco 371.74 Pharma Ranbaxy Laboratories 1154.63 3104.7 Glenmark Pharma OVERALL OPPORTUNITY Lupin Pharmaceuticals Ranbaxy Laboratories SHARED OPPORTUNITY* Dr. Reddy's Laboratories 13.54 Sun Pharma Natco Pharma EXCLUSIVE OPPORTUNITY* 3.80 Dr. Reddy's Laboratories 9.6 Glenmark Pharma Natco Pharma 6.58 4.93 0.45 2.10 Sun Pharma No. of brands 3 Lupin Pharmaceuticals 1.70 Lupin Pharmaceuticals 0.26 1.55 No. of brands 2 Ranbaxy Laboratories 28.05 No. of brands 3 No. of brands 12 Glenmark Pharma 4.48 Dr. Reddy's Laboratories Figures in $bn * The company is the sole FTF, or first to file, and has an exclusive right to sell an off-patent drug for 180 days; figures in billion are annual sales in the US. 1.65 27.63 No. of 8 brands No. of brands 3 2 6 No. of brands 4 Sun Pharma 32 17 29 27.79 Figures in $bn Where the company shares the 180-day exclusivity period along with other drug makers, as well as opportunities beyond that period Figures in $bn Source: JM Financial I T I IT Ranbaxy Laboratories Natco Pharma Glenmark Pharma Lupin Pharmaceuticals Or. Reddy's Laboratories Sun Pharma

BOOSTER DOSE OF OPPORTUNITY

shared by daSantosh on Oct 19
165 views
0 shares
0 comments
Indian companies could reap huge profits with the generic copies of drugs that are set to go off-patent between 2012 and 2016. Here is a snapshot of opportunities for the top six.

Category

Health
Did you work on this visual? Claim credit!

Get a Quote

Embed Code

For hosted site:

Click the code to copy

For wordpress.com:

Click the code to copy
Customize size